Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

Table 3 Univariate analysis of tumor and treatment characteristics on progression-free and overall survival

	PFS Hazard ratio (95% CI)	p-value	OS Hazard ratio (95% CI)	p-value
Age at surgery		0.68		0.87
<60 years* (n = 31)	1		1
>60 years (n = 24)	1.15 (0.58 - 2.29)		1.07 (0.47 - 2.43)
Gender		0.19		0.68
Female* (n = 20)	1		1
Male (n = 35)	0.63 (0.32 - 1.23)		0.68 (0.30 - 1.55)
Response†		<0.05		<0.05
Yes* (n = 35)	1		1
No (n = 20)	5.01 (2.46 - 10.22)		6.81 (2.83 - 16.38)
Resection		<0.05		0.06
Complete* (n = 29)	1		1
Incomplete (n = 26)	2.44 (1.20 - 4.96)		2.28 (0.98 - 5.28)
Adjuvant therapy		0.81		0.69
Yes* (n = 46)	1		1
No (n = 9)	0.89 (0.34 - 2.31)		1.28 (0.38 - 4.32)
Location metastasis‡		0.52		0.57
Abdominal* (n = 33)	1		1
Liver (n = 22)	0.79 (0.45 - 1.40)		1.21 (0.63 - 2.30)

*Reference group; †response on systemic therapy; ‡patients with both liver and abdominal metastasis were grouped together in the abdominal group; ||surgery before start of systemic therapy. CI, confidence interval; OS, overall survival; PFS, progression-free survival.

ISSN: 1477-7819